Anthropic’s recent launch of a Bay Area wet lab for physical biology experiments, combined with its September 10 threat intelligence report detailing blocked attempts to use Claude models for gain-of-function research on pathogens like avian influenza, has sharpened trader focus on leak risks. The company’s expanding life sciences efforts, including the new Life Sciences Verification Program and partnerships for AI-controlled lab automation, heighten exposure to accidental releases or data exfiltration amid ongoing distillation attacks from Chinese labs. Competitive pressure from peers on safety benchmarks and Anthropic’s push for embedded evaluations with Accenture add scrutiny, while model releases and regulatory attention on dual-use AI capabilities remain key near-term catalysts for sentiment shifts.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourNOUVEAU
31 déc. 2026
31 décembre 2026
8%
30 juin 2027
16%
$3,990 Vol.
31 décembre 2026
$3,004 Vol.
8%
30 juin 2027
$985 Vol.
16%
This market will resolve to “Yes” if a pathogen developed, modified, or handled at a wet lab operated by Anthropic is confirmed to have escaped that facility between market creation and the specified date, 11:59 PM ET. Otherwise, this market will resolve to “No.”
Confirmation that the pathogen escaped the laboratory, research facility, diagnostic facility, or other controlled laboratory setting in which it was contained is required.
Investigations, speculation, statements that an escape is possible or has not been ruled out, or statements unverified by a consensus of credible reporting will not suffice.
The primary resolution source for this market will be a consensus of credible reporting.Anthropic’s recent launch of a Bay Area wet lab for physical biology experiments, combined with its September 10 threat intelligence report detailing blocked attempts to use Claude models for gain-of-function research on pathogens like avian influenza, has sharpened trader focus on leak risks. The company’s expanding life sciences efforts, including the new Life Sciences Verification Program and partnerships for AI-controlled lab automation, heighten exposure to accidental releases or data exfiltration amid ongoing distillation attacks from Chinese labs. Competitive pressure from peers on safety benchmarks and Anthropic’s push for embedded evaluations with Accenture add scrutiny, while model releases and regulatory attention on dual-use AI capabilities remain key near-term catalysts for sentiment shifts.
This market will resolve to “Yes” if a pathogen developed, modified, or handled at a wet lab operated by Anthropic is confirmed to have escaped that facility between market creation and the specified date, 11:59 PM ET. Otherwise, this market will resolve to “No.”
Confirmation that the pathogen escaped the laboratory, research facility, diagnostic facility, or other controlled laboratory setting in which it was contained is required.
Investigations, speculation, statements that an escape is possible or has not been ruled out, or statements unverified by a consensus of credible reporting will not suffice.
The primary resolution source for this market will be a consensus of credible reporting.
Confirmation that the pathogen escaped the laboratory, research facility, diagnostic facility, or other controlled laboratory setting in which it was contained is required.
Investigations, speculation, statements that an escape is possible or has not been ruled out, or statements unverified by a consensus of credible reporting will not suffice.
The primary resolution source for this market will be a consensus of credible reporting.
Marché ouvert : Sep 18, 2026, 8:27 PM ET
Volume
$3,990Date de fin
1 juil. 2027Marché ouvert
Sep 18, 2026, 8:27 PM ETRésolveur
0x65070BE91...This market will resolve to “Yes” if a pathogen developed, modified, or handled at a wet lab operated by Anthropic is confirmed to have escaped that facility between market creation and the specified date, 11:59 PM ET. Otherwise, this market will resolve to “No.”
Confirmation that the pathogen escaped the laboratory, research facility, diagnostic facility, or other controlled laboratory setting in which it was contained is required.
Investigations, speculation, statements that an escape is possible or has not been ruled out, or statements unverified by a consensus of credible reporting will not suffice.
The primary resolution source for this market will be a consensus of credible reporting.Anthropic’s recent launch of a Bay Area wet lab for physical biology experiments, combined with its September 10 threat intelligence report detailing blocked attempts to use Claude models for gain-of-function research on pathogens like avian influenza, has sharpened trader focus on leak risks. The company’s expanding life sciences efforts, including the new Life Sciences Verification Program and partnerships for AI-controlled lab automation, heighten exposure to accidental releases or data exfiltration amid ongoing distillation attacks from Chinese labs. Competitive pressure from peers on safety benchmarks and Anthropic’s push for embedded evaluations with Accenture add scrutiny, while model releases and regulatory attention on dual-use AI capabilities remain key near-term catalysts for sentiment shifts.
This market will resolve to “Yes” if a pathogen developed, modified, or handled at a wet lab operated by Anthropic is confirmed to have escaped that facility between market creation and the specified date, 11:59 PM ET. Otherwise, this market will resolve to “No.”
Confirmation that the pathogen escaped the laboratory, research facility, diagnostic facility, or other controlled laboratory setting in which it was contained is required.
Investigations, speculation, statements that an escape is possible or has not been ruled out, or statements unverified by a consensus of credible reporting will not suffice.
The primary resolution source for this market will be a consensus of credible reporting.
Confirmation that the pathogen escaped the laboratory, research facility, diagnostic facility, or other controlled laboratory setting in which it was contained is required.
Investigations, speculation, statements that an escape is possible or has not been ruled out, or statements unverified by a consensus of credible reporting will not suffice.
The primary resolution source for this market will be a consensus of credible reporting.
Volume
$3,990Date de fin
1 juil. 2027Marché ouvert
Sep 18, 2026, 8:27 PM ETRésolveur
0x65070BE91...Anthropic’s recent launch of a Bay Area wet lab for physical biology experiments, combined with its September 10 threat intelligence report detailing blocked attempts to use Claude models for gain-of-function research on pathogens like avian influenza, has sharpened trader focus on leak risks. The company’s expanding life sciences efforts, including the new Life Sciences Verification Program and partnerships for AI-controlled lab automation, heighten exposure to accidental releases or data exfiltration amid ongoing distillation attacks from Chinese labs. Competitive pressure from peers on safety benchmarks and Anthropic’s push for embedded evaluations with Accenture add scrutiny, while model releases and regulatory attention on dual-use AI capabilities remain key near-term catalysts for sentiment shifts.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes